Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

qilu pharma spain s.l. - ceftriaxonnatrium (hemiheptahydrat) - pulver till injektions-/infusionsvätska, lösning - 1 g - ceftriaxonnatrium (hemiheptahydrat) 1,193 g aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

qilu pharma spain s.l. - ceftriaxonnatrium (hemiheptahydrat) - pulver till injektions-/infusionsvätska, lösning - 2 g - ceftriaxonnatrium (hemiheptahydrat) 2,386 g aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - ceftriaxonnatrium (hemiheptahydrat); lidokainhydrokloridmonohydrat - pulver och vätska till injektionsvätska, lösning - 1 g - ceftriaxonnatrium (hemiheptahydrat) 1,19 g aktiv substans; lidokainhydrokloridmonohydrat 37,34 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymfom, b-cell - antineoplastiska medel - polivy i kombination med bendamustine och rituximab är indicerat för behandling av vuxna patienter med återfall/refraktär diffusa stora b-cellslymfom (dlbcl) som inte är kandidater för hematopoietisk stamcellstransplantation. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans